OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that the second milestone payment has been received from the Company’s licensee, Molteni Farmaceutici.
The company announced on March 28, 2025, that the company had entered into a license agreement which grants L. Molteni & C. dei F.lli Alitti, Società di Esercizio S.p.A (“Molteni Farmaceutici”) exclusive rights and commercial partnership to introduce BupiZenge™ in Europe (EU27, EES, Switzerland and the UK).
On June 2, 2026, the second milestone payment was received. The milestone payment was conditional upon European regulatory approval of OncoZenge’s Clinical Trial Application (CTA), which was received on May 26, 2026. The amount received by the company amounted to approximately SEK 5.9m. The amount will be reported in the company’s result and financial position in the second quarter of 2026.